OP0211 A Preliminary Investigation of “Treat-to-Target” Criteria Using BSAS, RAPID3 and Physician Global in Behcet’s Syndrome”
Identifieur interne : 001189 ( Main/Exploration ); précédent : 001188; suivant : 001190OP0211 A Preliminary Investigation of “Treat-to-Target” Criteria Using BSAS, RAPID3 and Physician Global in Behcet’s Syndrome”
Auteurs : Y. Yazici [États-Unis] ; Y. Bata [États-Unis] ; C. J. Swearingen [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Anca, Anca positivity, Anca status, Ankylosing spondylitis, Bsas, Cluster analysis, Constitutional symptoms, Diffuse membranoproliferative glomerulonephritis, Eosinophilic granulomatosis, Explant, Explant cultures, First line, Giant cell arteritis, Health index, Hierarchical cluster analysis, Infusion protocol, Internal medicine, Item pool, Item reduction, Jena university hospital jena, Mainritsan trial, Major relapse, Medical center, Outcome measure, Peripheral neuropathy, Renal involvement, Scientific abstracts friday, Sectional study, Significant improvement, Third line, Tlr2, Tlr2 activation, Tlr2 expression, Treatment changes, University hospital.
Abstract
Background We had developed a PRO measure for Behcet Syndrome (BS) BSAS (Behcet Syndrome Activity Scale), for use as an outcome measure in order to determine need for treatment changes, leading to more aggressive treatment and possible “treating to target” criteria Objectives To determine if change in treatment is associated with changes in the BSAS, physician global, (MDGL) and RAPID3 scores. Methods All BS patients seen at the center completed an MDHAQ, and a BSAS. Treatment changes defined as first line (colchicine, hydroxychloroquine, low dose prednisone), second line (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil) and third line (biologic agents-TNF inhibitor) were identified and then the predictive value of change in therapy with BSAS, RAPID3 and MDGL were estimated using general linear mixed models. Results 544 patients (female 74%, mean disease duration 4.9 years, age 35) over 1474 observations (average 3.5 observations per patient) were analyzed. BSAS quantified more differences than MDGL and RAPID3, identifying significant changes between no therapy and first line, third line, combination of first and second and all three (Table). All three outcomes were able to distinguish between no therapy and use of combination of first and second line therapies as well as usage of all three. Image/graphConclusions BSAS was the measure most strongly and commonly associated with therapy changes. Both MDGL and RAPID3 were more predictive of later level treatment changes where as BSAS was also useful early on with lower levels of disease activity. A patient outcome measure such as BSAS may be useful in documenting treatment responses in Behcet syndrome patients in routine care and may be developed further as a “treat to target” tool for BS. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.416
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002789
- to stream Istex, to step Curation: 002789
- to stream Istex, to step Checkpoint: 000241
- to stream Main, to step Merge: 001190
- to stream Main, to step Curation: 001189
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">OP0211 A Preliminary Investigation of “Treat-to-Target” Criteria Using BSAS, RAPID3 and Physician Global in Behcet’s Syndrome”</title>
<author><name sortKey="Yazici, Y" sort="Yazici, Y" uniqKey="Yazici Y" first="Y." last="Yazici">Y. Yazici</name>
</author>
<author><name sortKey="Bata, Y" sort="Bata, Y" uniqKey="Bata Y" first="Y." last="Bata">Y. Bata</name>
</author>
<author><name sortKey="Swearingen, C J" sort="Swearingen, C J" uniqKey="Swearingen C" first="C. J." last="Swearingen">C. J. Swearingen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4CB44B2BC8B819BC8D6FFD10B93AABBD71CF903C</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2013-eular.416</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-WC0ZQ594-L/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002789</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002789</idno>
<idno type="wicri:Area/Istex/Curation">002789</idno>
<idno type="wicri:Area/Istex/Checkpoint">000241</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000241</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Yazici Y:op:a:preliminary</idno>
<idno type="wicri:Area/Main/Merge">001190</idno>
<idno type="wicri:Area/Main/Curation">001189</idno>
<idno type="wicri:Area/Main/Exploration">001189</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">OP0211 A Preliminary Investigation of “Treat-to-Target” Criteria Using BSAS, RAPID3 and Physician Global in Behcet’s Syndrome”</title>
<author><name sortKey="Yazici, Y" sort="Yazici, Y" uniqKey="Yazici Y" first="Y." last="Yazici">Y. Yazici</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Rheumatology, NYU HJD</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Rheumatology, NYU HJD</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bata, Y" sort="Bata, Y" uniqKey="Bata Y" first="Y." last="Bata">Y. Bata</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Rheumatology, NYU HJD</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Rheumatology, NYU HJD</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Swearingen, C J" sort="Swearingen, C J" uniqKey="Swearingen C" first="C. J." last="Swearingen">C. J. Swearingen</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biostatistics, University of Arkansas, Arkansas</wicri:regionArea>
<placeName><region type="state">Arkansas</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biostatistics, University of Arkansas, Arkansas</wicri:regionArea>
<placeName><region type="state">Arkansas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">72</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="A123">A123</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Anca</term>
<term>Anca positivity</term>
<term>Anca status</term>
<term>Ankylosing spondylitis</term>
<term>Bsas</term>
<term>Cluster analysis</term>
<term>Constitutional symptoms</term>
<term>Diffuse membranoproliferative glomerulonephritis</term>
<term>Eosinophilic granulomatosis</term>
<term>Explant</term>
<term>Explant cultures</term>
<term>First line</term>
<term>Giant cell arteritis</term>
<term>Health index</term>
<term>Hierarchical cluster analysis</term>
<term>Infusion protocol</term>
<term>Internal medicine</term>
<term>Item pool</term>
<term>Item reduction</term>
<term>Jena university hospital jena</term>
<term>Mainritsan trial</term>
<term>Major relapse</term>
<term>Medical center</term>
<term>Outcome measure</term>
<term>Peripheral neuropathy</term>
<term>Renal involvement</term>
<term>Scientific abstracts friday</term>
<term>Sectional study</term>
<term>Significant improvement</term>
<term>Third line</term>
<term>Tlr2</term>
<term>Tlr2 activation</term>
<term>Tlr2 expression</term>
<term>Treatment changes</term>
<term>University hospital</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background We had developed a PRO measure for Behcet Syndrome (BS) BSAS (Behcet Syndrome Activity Scale), for use as an outcome measure in order to determine need for treatment changes, leading to more aggressive treatment and possible “treating to target” criteria Objectives To determine if change in treatment is associated with changes in the BSAS, physician global, (MDGL) and RAPID3 scores. Methods All BS patients seen at the center completed an MDHAQ, and a BSAS. Treatment changes defined as first line (colchicine, hydroxychloroquine, low dose prednisone), second line (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil) and third line (biologic agents-TNF inhibitor) were identified and then the predictive value of change in therapy with BSAS, RAPID3 and MDGL were estimated using general linear mixed models. Results 544 patients (female 74%, mean disease duration 4.9 years, age 35) over 1474 observations (average 3.5 observations per patient) were analyzed. BSAS quantified more differences than MDGL and RAPID3, identifying significant changes between no therapy and first line, third line, combination of first and second and all three (Table). All three outcomes were able to distinguish between no therapy and use of combination of first and second line therapies as well as usage of all three. Image/graphConclusions BSAS was the measure most strongly and commonly associated with therapy changes. Both MDGL and RAPID3 were more predictive of later level treatment changes where as BSAS was also useful early on with lower levels of disease activity. A patient outcome measure such as BSAS may be useful in documenting treatment responses in Behcet syndrome patients in routine care and may be developed further as a “treat to target” tool for BS. Disclosure of Interest None Declared</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Arkansas</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Yazici, Y" sort="Yazici, Y" uniqKey="Yazici Y" first="Y." last="Yazici">Y. Yazici</name>
</region>
<name sortKey="Bata, Y" sort="Bata, Y" uniqKey="Bata Y" first="Y." last="Bata">Y. Bata</name>
<name sortKey="Bata, Y" sort="Bata, Y" uniqKey="Bata Y" first="Y." last="Bata">Y. Bata</name>
<name sortKey="Swearingen, C J" sort="Swearingen, C J" uniqKey="Swearingen C" first="C. J." last="Swearingen">C. J. Swearingen</name>
<name sortKey="Swearingen, C J" sort="Swearingen, C J" uniqKey="Swearingen C" first="C. J." last="Swearingen">C. J. Swearingen</name>
<name sortKey="Yazici, Y" sort="Yazici, Y" uniqKey="Yazici Y" first="Y." last="Yazici">Y. Yazici</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001189 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001189 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:4CB44B2BC8B819BC8D6FFD10B93AABBD71CF903C |texte= OP0211 A Preliminary Investigation of “Treat-to-Target” Criteria Using BSAS, RAPID3 and Physician Global in Behcet’s Syndrome” }}
This area was generated with Dilib version V0.6.33. |